Submitted by Niranjan N. Singh, MD
Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China
Ling Mao; Huijuan Jin; MengdieWang; Yu Hu; Shengcai Chen; Quanwei He; Jiang Chang; Candong Hong;Yifan Zhou; DavidWang; Xiaoping Miao; Yanan Li, MD, PhD; Bo Hu, MD, PhD JAMANeurology JAMA Neurol. 2020: 77 (6): 683-690
Note From the Editor:
The goal of the AANEM News Science editorial members and staff are to keep it members informed about the latest scientific knowledge, developments and breakthroughs in neuromuscular diseases. Starting with this issue my colleagues and I will be highlighting important information as it relates, to COVID-19 and neuromuscular diseases. We will continue to provide our members with best practices information for electromyographers and neuromuscular clinicians to help them achieve the best care for our patients. For this reason, I would encourage all our members to read the practice guidelines at www.aanem.org/Practice/COVID-19-Guidance
. Working together we will overcome this pandemic.
This is a retrospective analysis of 214 patients from Wuhan, China with COVID-19, 126 patients (58.9%) non severe infection and 88 patients (41.1%) had severe infection according to respiratory status. Overall the manifestation of symptoms where classified into central nervous system-dizziness, headache, impaired consciousness, stroke, ataxia and seizure, peripheral nervous system-taste impairment, smell impairment, vision impairment and nerve pain, and skeletal muscle injury manifestation. Overall , 36.4% (78 patients) have had some short of neurologic manifestation. Peripheral nervous system involvement 8.9 %, impairment of taste 5.6 %, smell 5.1 %,vision 1.4% nerve pain 2.3 %, skeletal muscle injury 10.7 %, and headache 13.1 %. In patients with more severe infections, neurologic manifestations included acute stroke 5.7 %, impaired consciousness 14.8%, and skeletal muscle injury 19.3 %.
The finding that many patients presented early with neurologic symptoms, such as anosmia, ageusia, and myopathy, along with less severe respiratory symptoms suggests that neurologists may be confronted by patients presenting with new-onset neurologic symptoms. Reports have emphasized anosmia as a common early feature of COVID-19 illness, as in many upper respiratory tract infections. This small series may not reflect the entire spectrum of neurologic disease in COVID-19 disease.